Us Bancorp \De\ Prothena Corp Public LTD CO Transaction History

Us Bancorp \De\

$78.3 Billion
Q2 2025

A detailed history of Us Bancorp \De\ transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Us Bancorp \De\ holds 9,031 shares of PRTA stock, worth $68,093. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,031

Previous 512 1663.87%

Holding current value

$68,093

Previous $6,000 800.0%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 23, 2025	BUY	$4.58 - $12.14 $39,017 - $103,420	8,519 Added 1663.87%	9,031 $54,000
Q1 2025 May 08, 2025	SELL	$12.38 - $16.04 $4,320 - $5,597	-349 Reduced 40.53%	512 $6,000
Q4 2024 Feb 05, 2025	BUY	$11.95 - $18.35 $740 - $1,137	62 Added 7.76%	861 $11,000
Q3 2024 Oct 28, 2024	SELL	$16.73 - $24.79 $5,219 - $7,734	-312 Reduced 28.08%	799 $13,000
Q2 2024 Aug 06, 2024	SELL	$19.54 - $26.15 $410 - $549	-21 Reduced 1.86%	1,111 $22,000
Q1 2024 May 07, 2024	SELL	$24.75 - $40.66 $717 - $1,179	-29 Reduced 2.5%	1,132 $28,000
Q4 2023 Feb 09, 2024	SELL	$32.31 - $52.32 $97,608 - $158,058	-3,021 Reduced 72.24%	1,161 $42,000
Q3 2023 Nov 03, 2023	SELL	$47.3 - $70.6 $154,008 - $229,873	-3,256 Reduced 43.78%	4,182 $201,000
Q2 2023 Aug 09, 2023	SELL	$48.26 - $78.59 $22,778 - $37,094	-472 Reduced 5.97%	7,438 $507,000
Q1 2023 May 09, 2023	SELL	$46.97 - $58.27 $9,769 - $12,120	-208 Reduced 2.56%	7,910 $383,000
Q4 2022 Feb 13, 2023	BUY	$52.05 - $65.0 $382,931 - $478,205	7,357 Added 966.75%	8,118 $489,000
Q3 2022 Oct 27, 2022	SELL	$25.16 - $60.63 $10,038 - $24,191	-399 Reduced 34.4%	761 $46,000
Q1 2022 May 11, 2022	SELL	$30.27 - $49.22 $3,935 - $6,398	-130 Reduced 10.08%	1,160 $42,000
Q1 2021 Apr 28, 2021	BUY	$11.0 - $28.24 $1,430 - $3,671	130 Added 11.21%	1,290 $32,000
Q2 2020 Aug 07, 2020	SELL	$9.56 - $12.51 $755 - $988	-79 Reduced 6.38%	1,160 $12,000
Q1 2020 May 13, 2020	SELL	$7.54 - $15.77 $4,983 - $10,423	-661 Reduced 34.79%	1,239 $13,000
Q4 2019 Feb 04, 2020	BUY	$7.48 - $17.01 $5,535 - $12,587	740 Added 63.79%	1,900 $30,000
Q3 2019 Nov 08, 2019	BUY	$6.89 - $10.45 $2,859 - $4,336	415 Added 55.7%	1,160 $9,000
Q1 2019 May 08, 2019	SELL	$10.32 - $14.49 $123 - $173	-12 Reduced 1.59%	745 $9,000
Q4 2018 Feb 13, 2019	SELL	$8.73 - $13.74 $61 - $96	-7 Reduced 0.92%	757 $8,000
Q3 2018 Nov 01, 2018	BUY	$12.7 - $15.79 $152 - $189	12 Added 1.6%	764 $10,000
Q2 2018 Aug 08, 2018	SELL	$10.99 - $44.21 $1,450 - $5,835	-132 Reduced 14.93%	752 $11,000
Q1 2018 May 08, 2018	SELL	$27.95 - $45.04 $4,527 - $7,296	-162 Reduced 15.49%	884 $32,000
Q4 2017 Feb 02, 2018	BUY	$35.44 - $63.76 $6,556 - $11,795	185 Added 21.49%	1,046 $39,000
Q3 2017 Nov 13, 2017	BUY	$53.83 - $67.75 $46,347 - $58,332	861	861 $56,000

Others Institutions Holding PRTA

# of Institutions

193

Shares Held

45.1M

Call Options Held

264K

Put Options Held

56.4K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $354M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account